Lawrence Chan is a professional trader for well over 20 years. He is known for his research work in custom market breadth analysis and advanced analytical techniques on index and forex markets. His breakthrough research in market breadth analysis is incorporated into the trading platform NeoTicker from TickQuest Inc.
*** Trading foreign exchange on margin carries a high level of risk, and may not be suitable for all investors. Please read full disclaimer from my website. ***
Lawrence has numerous articles and trading models published in trading-related magazines and influential financial websites like Futures, Technical Analysis of Stocks and Commodities and Seeking Alpha here.
Since 2010, Lawrence has switched his focus to summarize and publish his life-long research work after a successful career at TickQuest Inc. as the chief software designer of the trading platform NeoTicker.
His eBook, Special Theory of Price Discovery, has profound impact in the financial industry as it revolutionizes the understanding and predictability of price movements in financial markets.
I run a model fund at Ken Kam's Marketocracy, where they do capital management using the best member mutual fund track records with extensive tabulations of alpha, beta, R-squared, and many other fund management evaluations. Marketocracy Capital Management offers SMA (Separately Managed Accounts) through FOLIOfn Institutional ($100,000 minimum accounts) set up to track the top 15 or so long-term track records (many 12 years plus) of the 30000 or so active members that run models at their site. My fund is one of those top models available for SMAs. My SMA investment fund now has a first year performance with double digit alpha. You can see the fund's performance chart at marketocracy.com (the Turtle Fund - symbol BPMF) and there is one in my profile over at TalkMarkets.
My fund methodology is high diversification, usually running around 40-60 stocks from many different sectors. I rarely weight any position much over 5%. I began at Marketocracy developing an analysis method I've labeled The Fractal Base Flow Model. I've been experimenting with variations of my basic methodology with 4 other funds and a 5th where I try new things. With my first and main model fund BPMF (Bruce Pile's Mutual Fund) I did my basic method for the first 7 years or so with an alpha over 30, then strayed a little into other analysis methods that did not work as well. For the SMA, I am using the methods proven to work well.
Marketocracy is a new way of investing that solves a lot of the problems in the industry today. When investors nowadays survey their options, they are perplexed by the mish mash of risk and fees. In mutual funds, you have regulated safety where managers must diversify with less than 10% of your money in any one name in the top of your weightings scheme, making for at least around 20 stocks at any one time. The SEC also prohibits the risk of leverage and investing in dangerous derivatives, etc. But this safety is typically viewed as a tradeoff with performance vs hedge funds, where all the dangerous stuff is allowed. But the sad result of all this danger is that most hedge funds fail. The average life of a hedge fund that makes it past the first year is just 5 years. More than two thirds of all hedge funds that ever existed are now dead. There is the fund of funds option, but the high turnover means that even they must select an all new portfolio of funds about every 5 years. This makes selecting proven long-term performers virtually impossible. A fund of hedge funds will typically not only charge the high hedge fund fees of 1%-4% management fee plus 15%-25% of your returns, but will also charge fees for running the fund of funds. They pile complication upon complication and charge you for it. "Oh, and the hedge fund industry as a whole hasn’t produced alpha/added value to simple portfolios for years, since its assets under management ballooned." [FTalphaville] With typical leverage, that has grown over 15 years from around 20% to over 40% now, you get 40%more risk than mutual fund rules with no significant added performance, just more costs. And because that added leverage risk is so often concentrated in the same areas by all the large funds, inducing systemic risk, when those bets go wrong they can go very wrong. With all the above, an investor must live with the risk of having just one fund manager, or picker of rotating funds in a fund of funds. Imagine a place where you could go to sign up for an account where you could review track records and styles and risk levels of not just one guy, but up to 15 or so, and check on your account signup form how you want to spread your money among these guys. And imagine that all these managers have had to compile top ranked hedge fund performance levels for up to 15 years under the safety level of SEC rules for mutual funds. And imagine you could get all this at roughly cost of a mutual fund. It would be like opening an account and checking the names of Peter Lynch, Warren Buffett, and all your favorite hedge fund managers to gang tackle your investment objectives. And as in any team sport, if one guy hits a cold streak, the others will carry him. No dependence on one manager. Well there is such a place - Marketocracy Capital Management. Here, thousands of people from all walks of life, from retired and active fund managers to ordinary individual investors, compete online with virtual funds. If your track record qualifies, you can open a GIPS account for real money tracking of your model fund and have client accounts track your model. My fund is one of those, ticker BPMF. FOLIOfn Institutional can open a client SMA where you can pick and choose from the best of the best long-term performers. To look into this: Phone: 1-877-462-4180 email: firstname.lastname@example.org web: marketocracy.com
I am a market obsessed investor that spends countless hours researching the economy. As a son of a credit trader, I tend to be highly skeptical of the stock market and its obsession with bubbles. My main focus is on the macro economic side of the financial markets. You may also see me talk about a trade or two as well.
I try to provide a strong financial resource for all types of investors using my research and a few contacts that I have on the street. I tend to be highly opinionated at times so let me apologize in advance if one of my rants offends someone!
See Seeking Alpha's policy on anonymous authors: http://seekingalpha.com/article/69847-seeking-alpha-policy-on-anonymous-authorship
CVTrader is a self-taught investor who started trading in early 2000 at the height of the tech bubble. Having learned many lessons in the subsequent downward ride, he adopted a value-oriented, comparative analysis-guided investing strategy. With a Ph.D. in biological science and working experience in the biotech/pharmaceutical industry, he pays special attention to small- and mid-cap biopharmaceutical companies with innovative products and solid balance sheets.
At the same time, he does recognize that equity trading is not an exact science, and that market can be irrational at times, so he also employs other techniques mainly leveraged ETFs to capitalize on short-term market swings.
The enormous advancement in the biological sciences that is taking place has begun to change the traditional way of practicing medicine. Far-reaching biological products are being approved and news about breakthroughs are occupying the media headlines. However, selecting the biotechnology firms for investment requires not only an understanding of the company's finances, but also deep knowledge of the company's potential and the potential and scientific validity of it's products and technologies.
Our Mission is evaluating biotechnology companies, their products, their technologies, scientists, managements, as well as their finances. Our goal is to impart our readers with the knowledge and insight so that they may have a heightened understanding and appreciation for the biotechnology industry.
The Prohost Letter has been in circulation since 1992. Our readers are comprised of venture capital, fund managers, investors, medical professionals and individuals with one common interest, biotechnology.
Prohost Letter is posted in the members areas on the www.prohostbiotech.com. around 40 times a year. Articles are posted several times a week for subscribers in TODAY'S HIGHLIGHTS section and in News & Comments sector for all website visitors
Cara Goldenberg is Founding Partner at Permian Investment Partners. Goldenberg got her undergraduate degree in chemistry in 2002 from Yale University in New Haven, Connecticut. Her first job out of college was working as a private-equity analyst at New York-based investment bank Morgan Stanley.
She then moved to Highbridge Capital Management LLC, the hedge- fund firm owned by JPMorgan Chase & Co., in 2003, and to Brahman Capital Corp., also in New York, a year later. She became that firm’s youngest partner, and oversaw a $2 billion European equity portfolio. She and two former Brahman colleagues started Permian with about $65 million in assets in August 2008 and it now manages about $100 million. Permian, which is named for the geologic period that ran from about 290 million to 250 million years ago, focuses on what it deems undervalued companies, mostly in Western Europe.
Currently a partner of HarborView Capital Management LLC, I have been in the business since 1984 where I started in the capital markets division of Shearson Lehman Brothers. From 1994 until 2005 I was the General Partner of Gulfstream Partners L.P. The fund strategy was a long/short equity across all sectors and all market caps. In 2005 I became the General Partner of HealthCare 250 L.P. which was a long/short equity fund that concentrated investments in small to mid-cap health care companies.
The Burrill Report is written for everyone who wants to understand how biotechnology operates as a business. Each month the publication focuses on the health of the industry and the strategies that will be needed to be successful. It provides actionable market intelligence on the latest global developments and trends in the life sciences industry. Available monthly, subscribers also benefit from monthly and quarterly market financial and business statistics on:
- Public companies
- venture financings
- Project Runway – Follow the global life sciences companies filing for and completing their IPOs – and their post market performances
- Clinical Trials successes and failures
- M&A and Partnering deals
- Periodic country features on Canada, Europe and emerging countries such as China & India.
In addition, BR provides in-depth coverage on specific sectors of life sciences including: Personalized Medicine; Diagnostics, Medical Devices and Biogreentech (Ag-Bio and Biofuels/Bioenergy). Through weekly Burrill Indices, the progress and prospects of biotech companies by size, from small through to blue-chip are also tracked.
Visit: The Burrill Report to obtain your sample issue (http://www.burrillreport.com/)
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
VFC is just a guy with an opinion. VFC's Stock House brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - the biotech, pharmaceutical and healthcare sectors. VFC's Stock House provides research, informational and opinion-based coverage of various companies and stocks in multiple sectors.
The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies. Do not Buy/Sell based solely on VFC's ideas or opinions.
The goal of VFC's Stock House is to 'call it like I see it' - while bringing new ideas, companies, and discussions to the eyes of investors and readers. This is supposed to be fun and new investors should not invest with the idea that this will 'pay the bills' or with the belief that a stock will just keep going up. DD is paramount, but so is sticking to pre-conceived entry and exit strategies and not letting emotional trading get in the way.
Goals must be realistic, if it sounds far fetched, then it probably is. Let the big boys eat the cake - the small investor is just trying to pick up some crumbs, and there's nothing wrong with that!